ALDX · XBRL financial data

Aldeyra Therapeutics financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ALDX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	24,681	44,937	47,306	29,459	48,225	25,663
General and administrative	9,985	11,283	15,374	13,335	11,892	9,602
Operating income (loss)	(36,421)	(56,220)	(62,680)	(42,794)	(60,117)	(35,265)
Interest income	292	185	2,349	7,323	6,192	3,324
Interest expense	1,904	1,742	1,694	2,071	1,926	1,905
Income tax expense (benefit)	(479)	0	0	0	1	0
Net income (loss)	(37,554)	(57,776)	(62,025)	(37,543)	(55,851)	(33,847)
Earnings per share, basic USD per share	—	(1.07)	(1.06)	(0.64)	(0.94)	(0.56)
Earnings per share, diluted USD per share	—	(1.07)	(1.06)	(0.64)	(0.94)	(0.56)
Weighted average shares, basic thousands of shares	—	54,042	58,406	58,943	59,485	60,057
Weighted average shares, diluted thousands of shares	—	54,042	58,406	58,943	59,485	60,057

Fiscal years (ALDX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	77,858	229,791	144,419	142,823	54,527	70,041
Marketable securities	0	0	29,882	0	46,624	0
Prepaid and other current assets	5,201	2,962	6,722	4,987	2,921	1,742
Total current assets	83,059	232,753	181,023	147,810	104,072	71,783
Property and equipment, net	60	32	19	6	0	0
Right-of-use asset	233	352	249	511	267	276
Total assets	83,353	233,137	181,292	148,327	104,607	72,059
Accounts payable	382	1,020	134	1,338	180	158
Accrued liabilities	8,135	10,523	14,066	5,536	12,118	6,120
Current portion of long-term debt	—	—	912	15,147	31	15,250
Total current liabilities	12,409	11,773	15,361	22,260	18,602	27,809
Long-term debt	11,434	15,504	14,923	0	15,000	0
Lease liability, non-current	0	125	0	272	0	0
Total liabilities	23,844	27,402	30,284	28,532	33,602	27,809
Accumulated deficit	(236,916)	(294,692)	(356,717)	(394,259)	(450,111)	(483,957)
Total stockholders' equity	59,509	205,736	151,008	119,795	71,005	44,250
Total liabilities and equity	83,353	233,137	181,292	148,327	104,607	72,059
Common shares outstanding (cover page) thousands of shares	47,247	58,099	58,576	58,896	59,709	60,183

Fiscal years (ALDX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(37,554)	(57,776)	(62,025)	(37,543)	(55,851)	(33,847)
Stock-based compensation	7,084	7,108	8,289	5,753	7,973	6,091
Net cash from operating activities	(37,493)	(42,556)	(56,637)	(30,326)	(43,209)	(33,346)
Purchases of property and equipment	—	8	16	0	—	—
Net cash from investing activities	29,024	(8)	(29,955)	30,000	(44,916)	47,736
Proceeds from issuing common stock	40,717	189,812	0	—	—	—
Net cash from financing activities	41,902	194,496	1,220	(1,270)	(171)	1,124
Net change in cash	33,432	151,933	(85,372)	(1,596)	(88,296)	15,514

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Aldeyra Therapeutics	45,090	not reported	(4,589)*	60.3M	9.8 quarters	Q2 FY26 10-QJun 30, 2026
Heron Therapeutics	20,721	not reported	(2,213)*	189.9M	19.3 quarters	Q2 FY26 10-QJun 30, 2026
Sagimet Biosciences	165,896	not reported	(11,099)*	not reported	21.6 quarters	Q2 FY26 10-QJun 30, 2026
Lifecore Biomedical	17,241	not reported	(2,189)*	37.9M	7.9 quarters	Q2 FY26 10-QJun 30, 2026
Annexon	199,270	not reported	(48,007)*	not reported	4.4 quarters	Q2 FY26 10-QJun 30, 2026
Precigen	16,329	54,978	(17,809)*	358.0M	2.1 quarters	Q2 FY26 10-QJun 30, 2026
SELLAS Life Sciences Group	138,343	not reported	(7,588)*	201.9M	18.2 quarters	Q2 FY26 10-QJun 30, 2026
DBV Technologies	165,700	1,600	(51,500)*	314.4M	3.2 quarters	Q3 FY26 10-QSep 30, 2026
Corvus Pharmaceuticals	18,905	not reported	(15,398)*	84.1M	14.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.